The $6.9B Exit Playbook: What Sophisticated Buyers Actually Pay For | Jean Pineault

In this episode of the WATSNEX Podcast, host Pascal Côté sits down with Jean Pineault, Global Head of Life Sciences Practice at Human Factor Enterprises, for a masterclass in enterprise value. Jean has spent 25 years inside biotech and life sciences companies and led three exits that produced 4x to 11x increases above initial valuation. His core argument: most founders are building a good company, when very few are deliberately building a valuable one — and those are not the same thing. Jean walks through his Enterprise Value Blueprint, a nine-pillar, 32-driver framework that maps every major lever a life sciences CEO can pull before a raise, a strategic partnership, or an exit. He and Pascal get into what a sophisticated buyer really sees in a data room, why regulatory readiness is an enterprise value killer rather than a driver, what commands a premium multiple, the Johnson & Johnson / Momenta acquisition as a case study in strategic value, and why stakeholder risk is the most persistent blind spot destroying deals. It's an essential conversation for any founder building with the intention of raising capital, attracting a strategic partner, or creating a meaningful exit. Key Takeaways You'll Learn: Good company vs. valuable company: why deliberate enterprise-value building is a different discipline than building great science — and how the gap is "institutional evidence." Enterprise value is the CEO's currency: what a defensible valuation actually rests on — EBITDA multiple, a defensible moat, and strategic uplift. What the strategic buyer sees: the J&J / Momenta lesson in how strategic fit, not revenue, drove a $6.9B exit. Regulatory readiness is a value killer, not a driver: why "clean" only prevents markdowns, and a defect puts the whole deal at risk. Multiples reward evidence, not effort: how companies commanding 15–20x operate as if a buyer could enter the data room in 90 days. Stakeholder risk is the #1 blind spot: why alignment, decision architecture, and authority quietly erode value — and buyers price it down. Whether you're a life sciences founder, an operator, or an investor, this episode is a rigorous, candid blueprint for building a company worth what you think it is — before the buyer arrives to define it for you. #EnterpriseValue #LifeSciences #Biotech #MergersAndAcquisitions #ExitStrategy #Fundraising #Valuation #Biopharma #FounderStrategy #PrivateEquity #DueDiligence #RegulatoryReadiness #StakeholderRisk #CommercialStrategy #WATSNEX #Podcast